Company news

Marvel Biosciences Corp news in 2023

Marvel Biosciences Corp's news releases, calls and decks from 2023, newest first.

View company

Marvel Biosciences Invited to Test MB-204 on Autism by French University

November 16, 2023

Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials

August 22, 2023

Marvel Highlights Key Asset at the 2023 Alzheimer's Association International Conference

July 10, 2023

Marvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to Enter Human Trials

April 20, 2023

Marvel Commences Final Study Required Prior to Initiating Human Trials

March 21, 2023

Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study

March 9, 2023

Marvel Biosciences Announces Closing of First Tranche of Debenture Offering

February 24, 2023

Marvel Biosciences Announces Proposed Debenture Offering

February 15, 2023

Marvel Biosciences Completes a Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer's Disease and Depression

January 6, 2023

Marvel Biosciences Successfully Completes its Short Term Dose Ranging Study in Rats and Dogs for MB-204

January 3, 2023

Decks in 2023